Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
about
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertensionBlood pressure lowering efficacy of renin inhibitors for primary hypertensionRenin inhibitorsAliskiren: the first renin inhibitor for clinical treatmentAliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trialsCombined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndromeLocal delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.Analysis of the proteolysis of bioactive peptides using a peptidomics approach.Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertensionPeptidomics approach to elucidate the proteolytic regulation of bioactive peptides.Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis.Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.Blood pressure lowering efficacy of renin inhibitors for primary hypertension.Liquid chromatography-tandem mass spectrometric assay for aliskiren, a novel renin inhibitor in micro-volumes of human plasma: a pharmacokinetic application in healthy South Indian male subjects.The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.A peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones.Renin and cardiovascular disease: Worn-out path, or new direction.Combined aliskiren and L-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension.Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.Aliskiren: An orally active renin inhibitor.Role of aliskiren in blood pressure control and renoprotectionNational trends in the ambulatory treatment of hypertension in the United States, 1997-2012.Anti-fibrotic effect of Aliskiren in rats with deoxycorticosterone induced myocardial fibrosis and its potential mechanismFirst-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pillEffect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials.Renin inhibitors in diabetes and hypertension: an update.Reversibility of the effects of aliskiren in the renal versus systemic circulation.Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjectsAliskiren in hypertension: evidence for its potential therapeutic valueEffects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical TrialRenin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Pharmacological management of renal fibrotic disease.Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.
P2860
Q24240959-10A4CC3E-DD61-4A5D-96A0-D056A20A5C19Q24241169-959DAC22-32E9-4FD0-991A-D787018B8590Q27021804-8249E8BC-85CD-4F66-82E1-C3A3288430C7Q28272666-4C3941FD-D631-4AF6-9AE0-F44DED13640DQ28304657-37376491-C82F-48B4-9C89-DF422913F13FQ30422214-A62ED6D4-E25A-4929-BE5F-3BF7D19AF30AQ30664624-3AC044A9-46D6-4DE7-ACF3-70398553E861Q33756874-2092A3A2-C8F0-423B-A21D-270C3C70C23CQ33840829-15B0D805-DB95-48C5-B547-78082021CF73Q34156850-70737FA9-8A64-4865-8CD3-C2E4182B719CQ34222114-715247F0-26D6-4297-B706-B041A3E2552FQ34247173-F6337B3B-9149-4861-AFB2-3E8864287872Q34268925-2BE36309-B5E2-4E13-9613-95BB9DD449EEQ34478776-9604FC9E-36F4-4685-92CF-7FAEB5B5C046Q34673504-ADE68704-B49E-457A-A983-995401E5D5CFQ34681386-21B41646-8B9A-4A96-A509-7E9FE1CB01A0Q34708093-3E238CB7-E740-441E-8005-A2A9579B5666Q34722663-B0AA36BA-73F9-4464-BB60-D379425FCE48Q34795373-82B97C89-5EF1-4A0F-BDD9-1E2F34555A1AQ34801804-4D515FC3-0839-42D9-8DD3-3F34E5AF5698Q34886548-C3B979EC-C0DD-4CDC-8F6F-7A9B8B0E2C35Q34905891-F0A4D6F0-58DB-4CC0-BEBD-8F90EFAAECB9Q34926825-CE7CA815-B824-4310-99FE-A125B1802823Q35000118-74E558E7-3A32-4B99-902C-88E0108B4B34Q35013037-A09E68F1-12C3-486A-B34B-90BD1D1629DBQ35026735-BDFE71AC-026B-46DD-BDC3-931045BA5BB3Q35147255-BF90A490-F96B-4A46-9E2A-F2EE5EEC1C9DQ35184393-021473C7-BCE1-40F5-9EFA-7D9C8100BA87Q35210508-7BC52DF0-CFED-494A-A315-CCBF6F92D67CQ35210518-C39281DB-15CD-4115-B677-959B35371801Q35210533-55D869B4-4243-435A-818C-27E6F85DF5ECQ35408572-7CC70558-8A53-45E2-B442-0672D74CDB72Q35728190-7E7815E6-67D6-4548-950E-21A2BEF666A2Q35758528-E65D4CAB-0CD0-467E-9508-88208EC3F7AEQ35827907-FEE963A5-53AA-456F-BFF3-5A88BE4B81A3Q35876368-9F394939-1D2A-4A35-BA2A-5EE815D68A4FQ36258891-C7C444AB-8F62-463C-9FEE-74FA3F114BD3Q36329456-E8976B77-31D3-4F85-A18E-EBB1F4080DC8Q36407348-1437593D-8F6F-4044-A688-4990C5448CF2Q36434830-B36B746C-1747-463C-BEE3-900D55E6C6AA
P2860
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@ast
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@en
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@nl
type
label
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@ast
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@en
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@nl
prefLabel
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@ast
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@en
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@nl
P2093
P3181
P1433
P1476
Aliskiren, a novel orally effe ...... ility in hypertensive patients
@en
P2093
Alan H Gradman
Juerg Nussberger
Martin P Bedigian
Robert L Lins
Roland E Schmieder
Yanntong Chiang
P304
P3181
P356
10.1161/01.CIR.0000156466.02908.ED
P407
P577
2005-03-01T00:00:00Z